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Tissue inhibitor of metalloproteinase-3 (TIMP-3) inhibits the activity of matrix metalloproteinase, which may play an important role in
carcinoma invasion and metastasis. We have investigated the relationship between TIMP-3 reduction and clinicopathological factors
in oesophageal squamous cell carcinoma (ESCC). We examined tissue specimens that had been removed from 90 patients with
thoracic oesophageal cancer who had undergone surgery between 1983 and 2001. Immunohistochemical staining was performed by
the standard streptavidin–biotin method. Immunostaining of TIMP-3 was seen in the cytoplasm of cancer cells and normal
oesophageal epithelial cells, particularly in cells located in shallow areas of the tumour. TIMP-3 preserved (þ), moderate (7), and
reduced ( ) cases accounted for 30, 27, and 33 of the 90 patients, respectively (33, 30, 37%). Significant correlations were observed
between TIMP-3 expression and depth of tumour invasion (P¼0.001), number of lymph node metastases (P¼0.003), infiltrative
growth pattern (P¼0.003), and disease stage (P¼0.005). The survival rates of patients with TIMP-3 ( ) cancer were significantly
lower than those of patients with TIMP-3 (þ) and TIMP-3 (7) cancer (P¼0.0003). The mean 5-year survival rates of patients with
TIMP-3 (þ), (7), and ( ) were 50, 58, and 21%, respectively. In conclusion, decreased expression of TIMP-3 protein correlates with
invasive activity and metastasis. This makes the prognosis for patients with cancer that has lost TIMP-3 significantly less favourable than
that for patients with cancer that has maintained TIMP-3.
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The extracellular matrix is an important structure in maintenance
of tissue organisation and in the suppression of cellular prolifera-
tion and migration. Excess destruction of the extracellular
matrix is associated with many pathologies, including
atherosclerosis, rheumatoid arthritis, and cancer progression
(Liotta et al, 1980; Tryggvason et al, 1987; Palletier et al, 1990).
The intricate balance between net extracellular matrix deposition
and degradation is controlled by a complex system of tightly
regulated protease enzymes and their endogenous inhibitors.
Matrix destruction is thought to be a key event in both the
local invasion and distant metastasis associated with tumour
progression, and genes that inhibit these processes may be
useful for cancer therapy. Matrix metalloproteinases (MMPs), a
family of Zn
2þ metalloproteinases involved in the degradation of
extracellular matrix macromolecules, are associated with tissue
destruction under various pathological conditions. Previous
experimental and clinicopathological studies have revealed a
good correlation between expression of MMPs and invasive
phenotype of tumour cells or frequency of metastasis
(Stetler-Stevenson et al, 1993; Sato et al, 1994). Expression of
MMP-1, -2, -3, -7, and -9 in oesophageal cancer has already been
reported (Shima et al, 1992; Ohashi et al, 2000). In addition,
Ohashi et al (2000) have reported the expression of tissue inhibitor
of MMP (TIMP)-1 and -2, MT1-MMP, and MT2-MMP by
immunohistochemical staining.
The TIMPs are a family of molecules that inhibit the proteolytic
activity of MMPs, which also play an important role in tumour
invasion and metastasis (Sato et al, 1992; Miyagi et al, 1995; Wang
et al, 1997).
TIMP-3 is a secreted 24-kDa protein that, unlike other TIMP
family members, binds to the extracellular matrix. Its functions
have been reported as inducing apoptosis of cancer cells (Ahonen
et al, 1998; Baker et al, 1999), and suppressing tumour growth and
angiogenesis (Anand-Apte et al, 1996, 1997; Bian et al, 1996).
Furthermore, TIMP-3 expression decreases at the invasive edge of
poorly differentiated adenocarcinoma of the human colon, which
suggests that a regional loss of TIMP-3 may contribute to their
increased invasiveness (Powe et al, 1997). However, the relation-
ship between TIMP-3 expression and clinical features (tumour
invasiveness, metastasis and prognosis) in patients with ESCC is
not known.
In this study, an immunohistochemical analysis of TIMP-3
protein expression was performed to determine the relationship
between TIMP-3 reduction and clinicopathological factors in
ESCC.
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Patients and tissue samples
The tissue specimens used had been removed from 90 patients
with thoracic ESCC who had undergone surgery at Gunma
University Hospital between 1983 and 2001. Written informed
consent to participate in the study was obtained from each patient
before surgery, according to the ethical guidelines of our
university. All patients underwent potentially curative surgery
without preoperative therapy. There were 76 men and 14 women,
aged 40–78 years (mean age: 60.9 years). Tumour stages were
classified according to the fifth edition of the TNM classification of
the International Union against Cancer (UICC). Evaluation of
tumour differentiation was based on histological criteria of the
guidelines of the Japanese Society for Esophageal Diseases (1999).
The mean postoperative follow-up period was 33.9 months (range:
6.2–192.2 months).
Specimens were fixed in 10% formaldehyde solution and
embedded in paraffin. We examined sections that contained both
a tumour-invasive portion and normal oesophageal epithelium.
Antibodies
The monoclonal antibody (Mab) specific for TIMP-3 (clone 136-
13H4) was purchased from Daiichi Fine Chemical Co. Ltd.,
Toyama, Japan.
Immunohistochemistry
Immunohistochemical staining was performed by the standard
streptavidin–biotin (SAB) method. Briefly, each 4-mm tissue
section was deparaffinised, then rehydrated and incubated with
fresh 0.3% H2O2 in methanol for 30min at room temperature.
After rehydration through a graded ethanol series, the sections
were autoclaved in 10mM citrate buffer (pH 6.0) at 1201C for
5min, then cooled to 301C. After incubation with normal rabbit
serum for 30min, the tissue sections were removed by blotting.
The sections were then incubated at 41C overnight with anti-TIMP-
3 Mab at a dilution of 1:800 in phosphate-buffered saline (PBS)
containing 1% bovine serum albumin, then washed in PBS and
incubated with secondary antibody for 30min at room tempera-
ture. Immunohistochemistry was performed using a Histofine
SAB-PO(M) kit (Nichirei, Tokyo, Japan). The chromogen was 3,30-
diaminobenzidine tetrahydrochloride, applied as a 0.02% solution
containing 0.0055% H2O2 in 50mM ammonium acetate – citric acid
buffer (pH 6.0). The sections were lightly counterstained with
haematoxylin. Negative controls were prepared by substituting
normal mouse serum for primary antibody, and no detectable
staining was evident.
Evaluation of immunostaining for TIMP-3 expression
We evaluated immunostaining of cancer cells in all layers of the
oesophageal epithelium. When more than 80% of carcinoma cells
in a given specimen were positively stained as well as normal
epithelium in the same section, the sample was classified as TIMP-3
preserved (TIMP-3 (þ)); when less than 30% were stained, as
TIMP-3 reduced (TIMP-3 ( )); and when 30–80% of cells were
stained, as TIMP-3 moderate (TIMP-3 (7)).
Statistical analysis
Statistical analysis was performed using unpaired two-group t test
for age and number of lymph node metastases. The w
2 test was
used to analyse the effects of sex, differentiation, location, and
TNM clinical classification. Survival curves were calculated by the
Kaplan–Meier method, and analysis was carried out by the log-
rank test.
Figure 1 Representative photomicrographs of tissue sections immunos-
tained for TIMP-3. (A) TIMP-3 was detected in the cytoplasm of the basal
cells, parabasal cells, and leucocytes in normal oesophageal epithelium (left
side). In this case, TIMP-3 expression in the cancer cells (right side) was
weaker than that in the normal epithelium. This case was regarded as TIMP-
3-reduced ( 100). (B) The arrowhead indicates primary oesophageal
cancer with TIMP-3 protein expression ( 100). This case was regarded as
TIMP-3 preserved. (C) High-power view of the immunohistochemistry.
TIMP-3 was detected in the cytoplasm of cancer cells ( 200).
Figure 2 Representative photomicrographs of tissue sections immunos-
tained for TIMP-3 ( 50). Black arrowheads indicate deep areas of tumour
invasion. Cancer cells from these areas did not express TIMP-3 protein.
White arrowheads indicate shallow areas of tumour, where cancer cells
expressed TIMP-3 protein.
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Relationship between TIMP-3 expression and
clinicopathological features
Tissue inhibitor of metalloproteinase-3 expression in ESCC was
investigated by immunohistochemical analysis of formalin-fixed,
paraffin-embedded specimens using a TIMP-3 specific Mab. In
normal oesophageal tissue, immunostaining of TIMP-3 was
detected in the cytoplasm of the basal cells, parabasal cells and
stromal cells (Figure 1A, B). Immunostaining of TIMP-3 was seen
in the cytoplasm of all cancer cells (Figure 1B, C). Expression of
TIMP-3 was preserved in shallow areas of the tumour, but it was
Table 1 The correlationship between clinicopathological characteristics and TIMP-3 expression
TOMP-3 preserve TOMP-3 moderate TOMP-3 reduce
Parameters Total (n¼30) (n¼27) (n¼33) P–value
Age (mean7s.d., years) 60.978.3 60.977.5 59.978.2 61.879.1 NS
Gender
Male 76 23 23 30
Female 14 7 4 3 0.295
Differentiation
Well 22 7 6 9
Moderate 45 15 15 15
Poor 23 8 6 9 0.957
Location
Upper 12 1 6 5
Mid-thora 55 21 18 16
Lower 23 8 3 12 0.060
TNM clinical classification
T
T1 34 20 9 5
T2 13 2 6 5
T3 37 8 11 18
T4 6 0 1 5 0.001
N
N0 36 16 11 9
N1 54 14 16 24 0.108
M
M0 74 28 21 25
M1 16 2 6 8 0.147
Stage
I2 3 1 5 4 4
II 28 7 12 9
III 23 6 5 12
IV 16 2 6 8 0.005
No. of lymph node metastases (mean7s.d.) — 1.371.8 3.175.9 2.573.4 0.003
Lymphatic invasion
ly ( )2 8 1 3 7 8
ly (+) 62 17 20 25 0.206
Blood vessel invasion
v (–) 49 18 14 17 0.756
v (+) 41 12 13 16
Infiltrative growth pattern
inf a 22 14 2 6
inf b 60 12 23 25
inf g 8 4 2 2 0.003
Intraepithelial spread
ie ( )4 5 1 4 1 0 2 1
ie (+) 45 16 17 12 0.111
Intramural metastasis
IM0 80 27 25 28
IM1 10 3 2 5 0.619
s.d.¼standard deviation.
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preserved, moderate, and reduced cases accounted for 30, 27, and
33 of the 90 patients, respectively (33, 30, 37%). The relationship
between the clinicopathological characteristics of patients with
ESCC and TIMP-3 expression is summarised in Table 1. A
significant correlation was observed between TIMP-3 expression
and depth of tumour invasion (P¼0.001), number of lymph node
metastases (P¼0.003), infiltrative growth pattern (P¼0.003), and
disease stage (P¼0.005). However, there was no significant
association with age, sex, tumour location, presence of regional
lymph node metastasis, lymphatic invasion, blood vessel invasion,
intraepithelial spread, intramural metastasis, or presence of distant
metastasis.
The survival rates of patients with TIMP-3 ( ) cancer were
significantly lower than those of patients with TIMP-3 (þ) and
TIMP-3 (7) cancer (P¼0.0003; Figure 3). The mean 5-year
survival rates of patients with TIMP-3 (þ), (7), and ( ) were 50,
58, and 21%, respectively. Multivariate analysis showed that TIMP-
3 overexpression was not a prognostic factor by itself, in contrast
to depth of tumour invasion, lymph node metastasis, or disease
stage (data not shown).
DISCUSSION
Our immunohistochemical results suggest that expression of
TIMP-3 protein is correlated with depth of tumour invasion, the
number of lymph node metastases and disease stage. The
expression of TIMP-3 protein was localised in shallow areas of
the tumour, and was reduced in deep areas of the same tumour. In
particular, no expression was observed at the invasive tumour
front. This result indicated that invading cancer cells had lost
their expression of TIMP-3. Furthermore, the prognosis for
patients with cancer that had lost TIMP-3 was significantly less
favourable than that for patients with TIMP-3 (þ) and TIMP-3
(7) cancer.
Bachman et al (1999) showed that loss of TIMP-3 expression is
associated with dense methylation of the 50-CpG island in cell lines
from many common human cancers. This methylation-associated
silencing of TIMP-3 is tumour-specific, and associated with lack of
TIMP-3 protein expression in primary cancers. Aberrant methyla-
tion of TIMP-3 was demonstrated in primary cancers of the
kidney, brain, colon, breast, and lung, but not in any of 41 normal
tissue samples. Reduced TIMP-3 expression in ESCC may also
have been caused by aberrant methylation in our study.
Baker et al (Ahonen et al, 1998; Baker et al, 1999) reported that
TIMP-3 expression inhibits invasion and induces apoptosis in
cancer cells. They used adenovirus-mediated gene delivery of
TIMP-1, -2, and -3 to melanoma, cervical carcinoma, and
fibrosarcoma cell lines. Their reports support ours. Tissue
inhibitor of metalloproteinase-3 expression may be unfavourable
for the survival of cancer cells, and cancer cells with a high grade of
malignancy (more invasive and fewer apoptotic cells) may not
express TIMP-3 for various reasons.
An imbalance between cell surface-associated proteinases and
their inhibitors (higher concentrations of MMPs and lower
concentrations of TIMPs) has been traditionally implicated in
tumour expansion. However, it has been reported that some
TIMPs function as growth factors (Hayakawa et al, 1992, 1994).
For example, TIMP-1 and TIMP-2 have erythroid potentiating
activity, and accelerate the growth of most cells (Hayakawa et al,
1992, 1994). Tissue inhibitor of metalloproteinase-3 has been
reported to stimulate the proliferation of growth-retarded,
nontransformed cells maintained under low-serum conditions
(Yang and Hawkes, 1992). These reports do not coincide with our
data, but growth activity is not always consistent with invasive
activity.
Other functions of TIMP-3 have been reported, including
suppression of tumour growth and angiogenesis (Anand-Apte
et al, 1996, 1997; Bian et al, 1996; Spurbeck et al, 2002; Qi et al,
2003). Qi et al have demonstrated the ability of TIMP-3 to inhibit
vascular endothelial growth factor (VEGF)-mediated angiogenesis
and identified the possible mechanism involved. In ESCC, VEGF
has been reported to be one of the most important angiogenesis
factors (Shih et al, 2000; Kato et al, 2002). Therefore, TIMP-3 may
suppress tumour angiogenesis indirectly by inhibiting the VEGF
angiogenesis signal, and in turn, tumour growth.
Mori et al (2000)investigated TIMP-1 expression of mRNA and
protein in ESCC, and reported that TIMP-1 expression is
correlated with high-grade malignant behavior, and is an
independent prognostic factor. The structure of the protein-coding
exons is similar in the Timp-1 and Timp-3 genes (Apte et al, 1995).
Moreover, TIMP-3 and TIMP-1 inhibition were quantitatively
similar, implying that all TIMPs are equally efficient in MMP
inhibition (Apte et al, 1995).
Decreasing expression of TIMP-3 in invasive oesophageal cancer
cells may indicate that one of the functions of TIMP-3 is
suppression of invasiveness. If cancers having invasive and
metastatic ability do not express TIMP-3, preserving or increasing
expression of TIMP-3 may lead to a novel cancer therapy. Matrix
metalloproteinase inhibitor has recently been developed, and is
undergoing trials as an investigational agent (Nozaki et al, 2003).
Combination therapy with MMP inhibitor and TIMP-3 enhance-
ment may be more effective than MMP inhibitor alone.
In conclusion, decreased expression of TIMP-3 protein corre-
lates with invasive activity and metastasis. This makes the
prognosis for patients with cancer that has lost TIMP-3
significantly less favourable than that for patients with cancer
that has maintained TIMP-3.
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Figure 3 Relationship between overall postoperative survival and TIMP-
3 expression. Patients with TIMP-3-reduced cancer had a significantly
poorer prognosis than those with TIMP-3 preserved or moderate
expression (5-year survival rates: TIMP-3 reduced, 21%; TIMP-3 moderate,
58%; TIMP-3 preserved, 50%; P¼0.0003).
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